A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients

Overview of attention for article published in OncoTargets and therapy, June 2016

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 25 Mendeley

Summary Policy documents X Dimensions citations

So far, Dimensions has found 10 publications that cite this research output.

10

The most recent citing publications are shown below. View all 10 publications that cite this research output on Dimensions.

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

Article in Therapeutic Advances in Medical Oncology (January 2023)

Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma

Article in BMC Gastroenterology (October 2022)

Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial

Article in The Oncologist (September 2021)